Unlabelled: There is a worldwide increase in the frequency of pulmonary carcinoma The only radical treatment at such patients is the operative one, but it is associated with a lot of complications.
Material And Methods: We presented 41 patients aged over 70 years old with non small cell pulmonary carcinoma who are performed pulmonary resection. The patients were staged as follows: stage IA - 5, stage IB - 7, stage IlIA - 9 patients. We performed 22 lobectomies, 4 bilobectomies and 15 pulmonectomies.
Results: Analyzing all the results, we found 5 years survival at 29.2%, 3 years survival at 46.3% and one year survival at 78% of the operated patients. We found complication in the postoperative period at 15 of the patients; only one patient died (2.4%).
Conclusions: We consider, that the precisely selected patients at the age between 70-76 years old would not influence significantly the postoperative and long-term results at patients with non small carcinoma of the lungs.
Download full-text PDF |
Source |
---|
Ocul Immunol Inflamm
January 2025
Universiti Malaya Eye Research Centre (UMERC), Department of Ophthalmology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Purpose: To shed light on one of the ocular adverse effects related to pembrolizumab.
Method: Case report and literature review.
Result: A 53-year-old gentleman with underlying Stage III B renal cell carcinoma with lung metastasis and gout presented in June 2021 with bilateral red eyes following Coronavirus disease (COVID-19) vaccination.
PLoS One
January 2025
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. AFB1 is synthesized by Aspergillus flavus and is known to widely contaminate foodstuffs, particularly maize, wheat, and groundnuts. The mechanism in which AFB1 causes genetic mutations has been well studied, however its metabolomic effects remained largely unknown.
View Article and Find Full Text PDFJ Epidemiol Glob Health
January 2025
Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, No.7, Chung Shan S. Rd., Zhongzheng District, Taipei City, 100225, Taiwan.
Background: Lipids are known to be involved in carcinogenesis, but the associations between lipid profiles and different lung cancer histological classifications remain unknown.
Methods: Individuals who participated in national adult health surveillance from 2012 to 2018 were included. For patients who developed lung cancer during follow-up, a 1:2 control group of nonlung cancer participants was selected after matching.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFMonaldi Arch Chest Dis
January 2025
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi.
Peripheral pulmonary lesions (PPLs) present a significant diagnostic challenge due to their location beyond the reach of traditional bronchoscopy. With lung cancer being the leading cause of cancer-related mortality worldwide, accurate and early diagnosis of PPLs is crucial. Virtual bronchoscopic navigation (VBN) combined with radial endobronchial ultrasound (R-EBUS) has emerged as a promising technique to enhance the diagnostic yield for these lesions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!